Insmed Inc. promoted Drayton Wise to chief commercial officer, effective immediately, the Bridgewater-based biopharmaceutical company announced May 23.
In addition to his current responsibilities leading the global Arikayce franchise and U.S. commercial activities, Wise will assume responsibility for the company’s global commercial functions and will serve on its executive committee.
“Drayton is a trusted leader who exemplifies patient focus. In his eight-year tenure at Insmed, he has played a pivotal role in building the U.S. commercial organization and successfully launching ARIKAYCE around the world. I am excited to expand Drayton’s responsibilities as we prepare to significantly extend our commercial reach,” Insmed Chair and CEO Will Lewis said in a statement.
Lewis added that this was a critical time for the promotion, as the company is commercializing its Arikayce drug in three major territories, among other initiatives. Arikayce, according to its website, is the first and only FDA-approved medication for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen.
Wise joined Insmed in 2014, earning several promotions and most recently serving as senior vice president, head of U.S., and general manager of Arikayce. He also worked for Novartis from 1999 to 2014.
Wise added, “I look forward to continuing to build our team globally and laying the groundwork for launching new products and indications as we prepare to serve many more patients with serious and rare diseases.”
Along with Wise’s promotion, the company announced that Chief Operating Officer Roger Adsett will now focus on overseeing Insmed’s overall business operations on a global basis.
